ClinicalTrials.gg
CompletedNCT00396331Updated Mar 13, 2014Results posted

AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts

A Phase 2 interventional study of G-CSF plus plerixafor in Autologous Stem Cell Transplantation, sponsored by Genzyme, a Sanofi Company. Completed at 8 sites in United States. Open to participants aged 18 Years to 78 Years. Per ClinicalTrials.gov, last updated 2014-03-13.

Sponsored by Genzyme, a Sanofi Company (part of Sanofi) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years to 78 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing Granulocyte Colony-Stimulating Factor in Multiple Myeloma — 1 open to participants now, 1 under way, 1 of them phase 3. Granulocyte Colony-Stimulating Factor · Multiple Myeloma.

Enrollment
5th of 28
100 · median 38
Started
2005
with 4 others
Phase 2
17 of 28
none open now
Registered
8th of 28
by date
Lead sponsor
7 of 28
Genzyme, a Sanofi Company

Among the 28 studies testing Granulocyte Colony-Stimulating Factor in Multiple Myeloma, this one is the 5th largest by enrollment, is one of 5 that started in 2005, is one of 17 in phase 2, and was the 8th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

1 of the 28 studies testing Granulocyte Colony-Stimulating Factor in Multiple Myeloma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Granulocyte Colony-Stimulating Factor

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 78 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing Granulocyte Colony-Stimulating Factor in Multiple Myeloma, or all of them as a file.
02

Study summary

This study evaluates the safety, efficacy, and pharmacokinetics (PK) of plerixafor given in addition to granulocyte-colony stimulating factor (G-CSF) for collection of peripheral blood stem cells (PBSCs) for autologous transplantation in patients who would benefit from an autologous stem cell transplant but have failed previous collections or collection attempts with a mobilization regimen of G-CSF alone, chemotherapy and G-CSF, or any other conventional therapy including cytokines, chemotherapy and cytokines and bone marrow harvests.

The only change to standard of care of a mobilization regimen that includes G-CSF is the addition of a dose of AMD3100 (plerixafor) on the evening prior to each day of apheresis.

Efficacy outcomes include quantification of CD34+ cells in the apheresis product and assessment of successful polymorphonuclear leukocyte (PMN) and platelet (PLT) engraftment after transplantation. PK outcomes include analysis of repeated doses of plerixafor.

Read the detailed description

This is a Phase 2, multicenter, prospective, open-label study. Once 70 patients have enrolled, subsequent patients enrolled should have a diagnosis of lymphoma. Patients who would benefit from an autologous stem cell transplant, who have failed previous collections or collection attempts with a mobilization regimen of granulocyte colony-stimulating factor (G-CSF) alone, chemotherapy and G-CSF, or any other conventional therapy including cytokines, chemotherapy and cytokines and bone marrow harvests, and who meet the inclusion/exclusion criteria are eligible to receive plerixafor as outlined in this protocol. The only change to standard of care of a mobilization regimen that includes G-CSF is the addition of a dose of plerixafor on the evening prior to each day of apheresis.

Patients will undergo mobilization with G-CSF (10 µg/kg) for 4 days. On Day 4, plerixafor (240 µg/kg) will be administered in the evening prior to the first apheresis and each subsequent evening prior to apheresis thereafter, such that there is a 10 to 11 hour interval between dosing and the initiation of apheresis. Patients will continue to receive G-CSF on each day of apheresis. Patients will undergo a minimum of 2 and a maximum of 7 aphereses or until ≥2*10\^6 CD34+ cells/kg are collected, whichever occurs first. In addition, the mobilization of NHL tumor cells and the pharmacokinetics of repeat doses of plerixafor will be examined.

After the last apheresis has been completed, or after the patient has collected ≥2*10\^6 CD34+ cells/kg, he/she will be treated with high-dose chemotherapy in preparation for transplantation. Patients will be transplanted with cells obtained from the G-CSF with plerixafor mobilization regimen. In the event that the minimum number of ≥2*10\^6 cells for transplantation are not obtained from the first mobilization with plerixafor, cells may be retained and pooled for transplantation with those from a second mobilization with plerixafor (or from prior mobilization with other agents), at the investigator's discretion. If a second mobilization with plerixafor is attempted, a minimum rest interval of one week should be allowed between the last apheresis of the first regimen and the first dose of G-CSF of the second. The number of CD34+ cells mobilized in the peripheral blood (PB), collected in the apheresis product, and the number of apheresis sessions performed will be measured. Success of the transplantation will be evaluated by the time to engraftment of polymorphonuclear leukocytes (PMN) and platelets (PLT). Participants will be assessed for durability of their transplant for 12 months after transplantation.

This study was previously posted by AnorMED, Inc. In November 2006, AnorMED, Inc. was acquired by Genzyme Corporation. Genzyme Corporation is the sponsor of the trial.

03

Conditions studied

  • Autologous Stem Cell Transplantation

Keywords

  • Multiple Myeloma
  • Non-Hodgkin's Lymphoma
  • autologous transplantation
  • AMD3100
  • stem cell mobilization
  • plerixafor
04

Who can participate

Ages eligible
18 Years to 78 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Eligible to undergo transplantation
  • Has failed previous collections or collection attempts with a mobilization regimen of granulocyte colony-stimulating factor (G-CSF), chemotherapy and G-CSF or any other conventional therapy including cytokines, chemotherapy and cytokines or bone marrow harvest.
  • Eastern Co-operative Oncology Group () performance status of 0 or 1
  • ≥3 weeks since last cycle of chemotherapy (thalidomide, dexamethasone, and Velcade™ are not considered prior chemotherapy for the purpose of this study) NOTE: Although thalidomide, dexamethasone, and Velcade™ are not considered prior chemotherapy for the purpose of this study, none are to be administered within 7 days prior to the first dose of G-CSF (see Exclusion Criteria).
  • The patient has recovered from all acute toxic effects of prior chemotherapy
  • White blood cell count (WBC) >2.5*10\^9/L
  • >1.5*10\^9/L
  • count >85*10\^9/L
  • Serum creatinine ≤1.5 mg/dl
  • >60 ml/min
  • (AST), alanine transaminase (ALT) and total \<2x (ULN)
  • Left ventricle >45% (by normal echocardiogram (ECHO) or multiple gated acquisition (MUGA) scan)
  • in one minute (FEV1) >60% of predicted or diffusion lung capacity for carbon monoxide (DLCO) ≥45% of predicted
  • No active infection of or C
  • Negative for
  • Signed
  • Women of agree to use an approved form of

Exclusion criteria

Exclusion Criteria:

  • Once 70 patients have enrolled, patients with diagnoses other than lymphoma are not eligible (eg, acute myeloid leukemia, chronic lymphocytic leukemia, or multiple myeloma).
  • A co-morbid condition which, in the view of the investigators, renders the patient at high risk from treatment complications
  • A residual acute medical condition resulting from prior chemotherapy
  • Received Neupogen™, thalidomide, dexamethasone, and/or Velcade™ within 7 days prior to the first dose of G-CSF
  • or carcinomatous meningitis
  • Acute infection
  • Fever (temperature >38°C/100.4°F)
  • Hypercalcaemia (>1 mg/dL above the )
  • Positive pregnancy test in female patients
  • Lactating females
  • Patients of unwilling to implement adequate
  • Patients whose actual body weight exceeds 175% of their ideal body weight
  • Patients who previously received experimental therapy within 4 weeks of enrolling in this protocol or who are currently enrolled in another experimental protocol during the Mobilization phase
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    G-CSF plus Plerixafor

    Drug: G-CSF plus plerixafor

Interventions

  • DrugG-CSF plus plerixafor

    Drug pages: Granulocyte Colony-Stimulating Factor · Plerixafor

    Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 7 aphereses or until ≥ 2\*10\^6 CD34+ cells/kg were collected.

    Also known as: AMD3100, Mozobil

06

What researchers measure

Primary outcomes

  1. Overall Participant Counts Summarizing Adverse Events (AEs) During the Treatment Period

    Number of participants with adverse events (AEs) collected from Day 1 (start of G-CSF mobilization) to the day before starting chemotherapy. AEs were graded by the investigator using the World Health Organization (WHO) Adverse Event Grading Scale and were assessed for severity (mild, moderate, severe, life-threatening) and relatedness to study treatment (5 point scale from 'not related' to 'definitely related').

    Time frame: Day 1 to approximately day 38

  2. Proportion of Participants Who Achieved ≥2*10^6 CD34+ Cells/kg Following Treatment With Plerixafor and G-CSF

    Proportion of participants who reached the target of at least 2\*10\^6 CD34+ cells/kg collected during up to 7 aphereses.

    Time frame: Day 5 to Day 11 (up to 7 apheresis)

  3. Proportion of Participants Who Achieved ≥5*10^6 CD34+ Cells/kg Following Treatment With Plerixafor and G-CSF

    Proportion of participants who reached the target of at least 5\*10\^6 CD34+ cells/kg collected during up to 7 apheresis.

    Time frame: Day 5 to Day 11 (up to 7 aphereses)

Secondary outcomes

  1. Median Number of Days to Polymorphonuclear Leukocyte (PMN) Engraftment

    The number of days from transplantation to successful engraftment as measured by PMN \>=0.5\*10\^9 /L for 3 days or \>=1.0\*10\^9 /L for 1 day.

    Time frame: approximately 2 months (1 month post transplant)

  2. Median Number of Days to Platelet (PLT) Engraftment

    The number of days from transplantation to successful engraftment as measured by platelet value of \>=20\*10\^9/L for 7 days without transfusion.

    Time frame: Approximately 2 months (1 month post transplant)

  3. Number of Participants With Durable Engraftment 12 Months After Autologous Transplantation

    The number of participants maintaining a durable graft 12 months after transplantation. A durable graft was defined as maintenance of normal blood counts: PLT \>50\*10\^9/L without transfusion for at least 2 weeks prior to the visit; hemoglobin level \>= 10 g/dL with no erythropoietin or transfusions for at least 1 month prior to the visit; and absolute neutrophil count (ANC) \> 1,000 (1\*10\^9/L) with no G-CSF for at least 1 week prior to the visit.

    Time frame: Approximately 13 months (12 months post transplant )

  4. Number of Participants With Non-Hodgkin's Lymphoma (NHL) Who Had Evidence of Tumor Cell Mobilization After G-CSF or Plerixafor Administration

    The number of participants with Bcl2 translocation in post-treatment samples.

    Time frame: Up to Day 7

  5. Number of Participants Who Achieved ≥2*10^6 CD34+ Cells/kg Collected During Both Courses of Treatment With Plerixafor and G-CSF

    Number of participants who had at least 2\*10\^6 CD34+ cells/kg collected by apheresis during both the first and the second courses of treatment together.

    Time frame: Day 5 up to Month 6 (up to 7 aphereses in each course of treatment)

  6. Number of Participants Who Achieved ≥5*10^6 CD34+ Cells/kg Collected During Both Courses of Treatment With Plerixafor and G-CSF

    Number of participants who had at least 5\*10\^6 CD34+ cells/kg collected by apheresis during both the first and the second courses of treatment together.

    Time frame: Day 5 up to Month 6 (up to 7 aphereses in each course of treatment)

  7. Maximum Observed Plasma Concentration (Cmax) on Day 4

    Maximum plasma concentration (Cmax) of plerixafor following daily doses of 240 µg/kg plerixafor, determined directly from the concentration-time data.

    Time frame: Day 4 (following first plerixafor administration)

  8. Maximum Observed Plasma Concentration (Cmax) on Day 7

    Maximum plasma concentration (Cmax) of plerixafor following daily doses of 240 µg/kg plerixafor, determined directly from the concentration-time data.

    Time frame: Day 7 (following fourth plerixafor administration)

  9. Time to Maximum Plasma Concentration (Tmax) on Day 4

    Time to maximum plasma concentration (Tmax) of plerixafor following daily doses of 240 µg/kg plerixafor, determined directly from the concentration-time data

    Time frame: Day 4 (following first plerixafor administration)

  10. Time to Maximum Plasma Concentration (Tmax) on Day 7

    Time to maximum plasma concentration (Tmax) of plerixafor following daily doses of 240 µg/kg plerixafor, determined directly from the concentration-time data

    Time frame: Day 7 (following fourth plerixafor administration)

  11. Area Under the Steady-state Plasma Concentration Time Curve From Time Zero to the Last Quantifiable Sample (AUC0-last) on Day 4

    Area under the steady-state plasma concentration time curve from time zero to the last quantifiable sample after each plerixafor daily dose of 240 µg/kg, determined using the linear trapezoidal rule.

    Time frame: Days 4 -5 (following first plerixafor administration)

  12. Area Under the Steady-state Plasma Concentration Time Curve From Time Zero to the Last Quantifiable Sample (AUC0-last) on Day 7

    Area under the steady-state plasma concentration time curve from time zero to the last quantifiable sample after each plerixafor daily dose of 240 µg/kg, determined using the linear trapezoidal rule.

    Time frame: Days 7-8 (following fourth plerixafor administration)

07

Results

Posted Dec 2, 2010

Participant flow

Participant flow — Overall Study
MilestoneG-CSF Plus Plerixafor
Started100
Number of participants treated100
Number of participants transplanted87
Completed68
Not completed32
Withdrew: Failed to mobilize - no transplant8
Withdrew: Did not go on to transplant5
Withdrew: Lost to follow-up3
Withdrew: Death16

Outcome measures

PrimaryOverall Participant Counts Summarizing Adverse Events (AEs) During the Treatment Period

Number of participants with adverse events (AEs) collected from Day 1 (start of G-CSF mobilization) to the day before starting chemotherapy. AEs were graded by the investigator using the World Health Organization (WHO) Adverse Event Grading Scale and were assessed for severity (mild, moderate, severe, life-threatening) and relatedness to study treatment (5 point scale from 'not related' to 'definitely related').

Time frame:
Day 1 to approximately day 38
Reported as:
Number · Participants
Overall Participant Counts Summarizing Adverse Events (AEs) During the Treatment Period
ParticipantsNon-Hodgkin's LymphomaHodgkin's DiseaseMultiple MyelomaOther CancersAll Patients
Participants Reporting At Least 1 AE65209397
Adverse Events by Severity -Mild42127162
Adverse Events by Severity -Moderate1881027
Adverse Events by Severity -Severe50128
Adverse Events by Severity -Life Threatening00000
AE Relationship to Study Drug -Not Related1044018
AE Relationship to Study Drug-Probably Not Related821011
AE Relationship to Study Drug -Possibly Related1641021
AE Relationship to Study Drug -Probably Related2222127
AE Relationship to Study Drug -Definitely Related981220
PrimaryProportion of Participants Who Achieved ≥2*10^6 CD34+ Cells/kg Following Treatment With Plerixafor and G-CSF

Proportion of participants who reached the target of at least 2\*10\^6 CD34+ cells/kg collected during up to 7 aphereses.

Time frame:
Day 5 to Day 11 (up to 7 apheresis)
Reported as:
Number · Proportion of Participants
Proportion of Participants Who Achieved ≥2*10^6 CD34+ Cells/kg Following Treatment With Plerixafor and G-CSF
Proportion of ParticipantsNon-Hodgkin's LymphomaHodgkin's DiseaseMultiple MyelomaOther CancersAll Patients
Proportion of Participants Who Achieved ≥2*10^6 CD34+ Cells/kg Following Treatment With Plerixafor and G-CSF.773.7141.00.667.780
SecondaryMedian Number of Days to Polymorphonuclear Leukocyte (PMN) Engraftment

The number of days from transplantation to successful engraftment as measured by PMN \>=0.5\*10\^9 /L for 3 days or \>=1.0\*10\^9 /L for 1 day.

Time frame:
approximately 2 months (1 month post transplant)
Reported as:
Median · Days
Median Number of Days to Polymorphonuclear Leukocyte (PMN) Engraftment
DaysNon-Hodgkin's LymphomaHodgkin's DiseaseMultiple MyelomaOther CancersAll Patients
Median Number of Days to Polymorphonuclear Leukocyte (PMN) Engraftment12.0 (2.0 to 19.0)12.0 (11.0 to 15.0)13.0 (9.0 to 16.0)10.0 (7.0 to 13.0)12.0 (2.0 to 19.0)
SecondaryMedian Number of Days to Platelet (PLT) Engraftment

The number of days from transplantation to successful engraftment as measured by platelet value of \>=20\*10\^9/L for 7 days without transfusion.

Time frame:
Approximately 2 months (1 month post transplant)
Reported as:
Median · Days
Median Number of Days to Platelet (PLT) Engraftment
DaysNon-Hodgkin's LymphomaHodgkin's DiseaseMultiple MyelomaOther CancersAll Patients
Median Number of Days to Platelet (PLT) Engraftment21.0 (7.0 to 88.0)21.0 (15.0 to 81.0)19.0 (16.0 to 24.0)26.0 (3.0 to 49.0)21.0 (3.0 to 88.0)
SecondaryNumber of Participants With Durable Engraftment 12 Months After Autologous Transplantation

The number of participants maintaining a durable graft 12 months after transplantation. A durable graft was defined as maintenance of normal blood counts: PLT \>50\*10\^9/L without transfusion for at least 2 weeks prior to the visit; hemoglobin level \>= 10 g/dL with no erythropoietin or transfusions for at least 1 month prior to the visit; and absolute neutrophil count (ANC) \> 1,000 (1\*10\^9/L) with no G-CSF for at least 1 week prior to the visit.

Time frame:
Approximately 13 months (12 months post transplant )
Reported as:
Number · Participants
Number of Participants With Durable Engraftment 12 Months After Autologous Transplantation
ParticipantsNon-Hodgkin's LymphomaHodgkin's DiseaseMultiple MyelomaOther CancersAll Patients
Number of Participants With Durable Engraftment 12 Months After Autologous Transplantation44147—65
PrimaryProportion of Participants Who Achieved ≥5*10^6 CD34+ Cells/kg Following Treatment With Plerixafor and G-CSF

Proportion of participants who reached the target of at least 5\*10\^6 CD34+ cells/kg collected during up to 7 apheresis.

Time frame:
Day 5 to Day 11 (up to 7 aphereses)
Reported as:
Number · Proportion of Participants
Proportion of Participants Who Achieved ≥5*10^6 CD34+ Cells/kg Following Treatment With Plerixafor and G-CSF
Proportion of ParticipantsNon-Hodgkin's LymphomaHodgkin's DiseaseMultiple MyelomaOther CancersAll Patients
Proportion of Participants Who Achieved ≥5*10^6 CD34+ Cells/kg Following Treatment With Plerixafor and G-CSF0.2880.4290.700.6670.37
SecondaryNumber of Participants With Non-Hodgkin's Lymphoma (NHL) Who Had Evidence of Tumor Cell Mobilization After G-CSF or Plerixafor Administration

The number of participants with Bcl2 translocation in post-treatment samples.

Time frame:
Up to Day 7

No measurements were reported for this outcome.

SecondaryNumber of Participants Who Achieved ≥2*10^6 CD34+ Cells/kg Collected During Both Courses of Treatment With Plerixafor and G-CSF

Number of participants who had at least 2\*10\^6 CD34+ cells/kg collected by apheresis during both the first and the second courses of treatment together.

Time frame:
Day 5 up to Month 6 (up to 7 aphereses in each course of treatment)
Reported as:
Number · Participants
Number of Participants Who Achieved ≥2*10^6 CD34+ Cells/kg Collected During Both Courses of Treatment With Plerixafor and G-CSF
ParticipantsNon-Hodgkin's LymphomaHodgkin's DiseaseMultiple MyelomaOther CancersAll Patients
Number of Participants Who Achieved ≥2*10^6 CD34+ Cells/kg Collected During Both Courses of Treatment With Plerixafor and G-CSF541810284
SecondaryNumber of Participants Who Achieved ≥5*10^6 CD34+ Cells/kg Collected During Both Courses of Treatment With Plerixafor and G-CSF

Number of participants who had at least 5\*10\^6 CD34+ cells/kg collected by apheresis during both the first and the second courses of treatment together.

Time frame:
Day 5 up to Month 6 (up to 7 aphereses in each course of treatment)
Reported as:
Number · Participants
Number of Participants Who Achieved ≥5*10^6 CD34+ Cells/kg Collected During Both Courses of Treatment With Plerixafor and G-CSF
ParticipantsNon-Hodgkin's LymphomaHodgkin's DiseaseMultiple MyelomaOther CancersAll Patients
Number of Participants Who Achieved ≥5*10^6 CD34+ Cells/kg Collected During Both Courses of Treatment With Plerixafor and G-CSF2197239
SecondaryMaximum Observed Plasma Concentration (Cmax) on Day 4

Maximum plasma concentration (Cmax) of plerixafor following daily doses of 240 µg/kg plerixafor, determined directly from the concentration-time data.

Time frame:
Day 4 (following first plerixafor administration)
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) on Day 4
ng/mLPK Subpopulation
Maximum Observed Plasma Concentration (Cmax) on Day 4796 ± 305
SecondaryMaximum Observed Plasma Concentration (Cmax) on Day 7

Maximum plasma concentration (Cmax) of plerixafor following daily doses of 240 µg/kg plerixafor, determined directly from the concentration-time data.

Time frame:
Day 7 (following fourth plerixafor administration)
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) on Day 7
ng/mLPK Subpopulation
Maximum Observed Plasma Concentration (Cmax) on Day 7894 ± 227
SecondaryTime to Maximum Plasma Concentration (Tmax) on Day 4

Time to maximum plasma concentration (Tmax) of plerixafor following daily doses of 240 µg/kg plerixafor, determined directly from the concentration-time data

Time frame:
Day 4 (following first plerixafor administration)
Reported as:
Median · Hours
Time to Maximum Plasma Concentration (Tmax) on Day 4
HoursPK Subpopulation
Time to Maximum Plasma Concentration (Tmax) on Day 40.500 (0.0500 to .750)
SecondaryTime to Maximum Plasma Concentration (Tmax) on Day 7

Time to maximum plasma concentration (Tmax) of plerixafor following daily doses of 240 µg/kg plerixafor, determined directly from the concentration-time data

Time frame:
Day 7 (following fourth plerixafor administration)
Reported as:
Median · Hours
Time to Maximum Plasma Concentration (Tmax) on Day 7
HoursPK Subpopulation
Time to Maximum Plasma Concentration (Tmax) on Day 70.500 (0.417 to 0.600)
SecondaryArea Under the Steady-state Plasma Concentration Time Curve From Time Zero to the Last Quantifiable Sample (AUC0-last) on Day 4

Area under the steady-state plasma concentration time curve from time zero to the last quantifiable sample after each plerixafor daily dose of 240 µg/kg, determined using the linear trapezoidal rule.

Time frame:
Days 4 -5 (following first plerixafor administration)
Reported as:
Mean · ng*h/mL
Area Under the Steady-state Plasma Concentration Time Curve From Time Zero to the Last Quantifiable Sample (AUC0-last) on Day 4
ng*h/mLPK Subpopulation
Area Under the Steady-state Plasma Concentration Time Curve From Time Zero to the Last Quantifiable Sample (AUC0-last) on Day 44578 ± 1715
SecondaryArea Under the Steady-state Plasma Concentration Time Curve From Time Zero to the Last Quantifiable Sample (AUC0-last) on Day 7

Area under the steady-state plasma concentration time curve from time zero to the last quantifiable sample after each plerixafor daily dose of 240 µg/kg, determined using the linear trapezoidal rule.

Time frame:
Days 7-8 (following fourth plerixafor administration)
Reported as:
Mean · ng*h/mL
Area Under the Steady-state Plasma Concentration Time Curve From Time Zero to the Last Quantifiable Sample (AUC0-last) on Day 7
ng*h/mLPK Subpopulation
Area Under the Steady-state Plasma Concentration Time Curve From Time Zero to the Last Quantifiable Sample (AUC0-last) on Day 75496 ± 1339

Adverse events

Collected over First day of G-CSF mobilization to the day prior to chemotherapy/ablative treatment in preparation for the first transplant. This timeframe includes G-CSF and plerixafor administration, and the rest period.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Non-Hodgkin's Lymphoma—4/66 (6.1%)64/66 (97%)
Hodgkin's Disease—0/21 (0%)20/21 (95.2%)
Multiple Myeloma—1/10 (10%)9/10 (90%)
Other Cancers—1/3 (33.3%)3/3 (100%)
Most frequent serious events
Most frequent serious events
EventNon-Hodgkin's LymphomaHodgkin's DiseaseMultiple MyelomaOther Cancers
Intestinal obstructionGastrointestinal disorders0/660/210/101/3
AnxietyPsychiatric disorders0/660/211/100/3
Atrial fibrillationCardiac disorders1/660/210/100/3
PancreatitisGastrointestinal disorders1/660/210/100/3
Catheter site infectionInfections and infestations1/660/210/100/3
Central line infectionInfections and infestations1/660/210/100/3
Pneumonia aspirationRespiratory, thoracic and mediastinal disorders1/660/210/100/3
Most frequent other events
Showing 10 of 152
Most frequent other events
EventNon-Hodgkin's LymphomaHodgkin's DiseaseMultiple MyelomaOther Cancers
FatigueGeneral disorders28/668/214/102/3
Injection site painGeneral disorders2/660/210/102/3
Injection site pruritusGeneral disorders5/660/210/102/3
HypokalaemiaMetabolism and nutrition disorders13/662/212/102/3
DiarrhoeaGastrointestinal disorders21/667/214/100/3
NauseaGastrointestinal disorders15/666/213/101/3
VomitingGastrointestinal disorders5/662/210/101/3
Catheter site painGeneral disorders4/661/212/101/3
Injection site erythemaGeneral disorders18/666/212/101/3
Breath sounds abnormalInvestigations0/660/210/101/3

Baseline characteristics

Age, Continuous
Age, Continuous(years)Non-Hodgkin's LymphomaHodgkin's DiseaseMultiple MyelomaOther CancersTotal
Mean57.0 ± 10.045.6 ± 15.562.6 ± 11.332.7 ± 28.954.4 ± 13.6
Sex: Female, Male
Sex: Female, Male(Participants)Non-Hodgkin's LymphomaHodgkin's DiseaseMultiple MyelomaOther CancersTotal
Female29105145
Male37115255
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Non-Hodgkin's LymphomaHodgkin's DiseaseMultiple MyelomaOther CancersTotal
Caucasian60179389
Black or African American31105
Asian21003
Hispanic/Latino12003
08

Study locations

8 sites
  • City of Hope National Medical Center'
    Duarte, California 91010, United States
  • H. Lee Moffitt Cancer Center
    Tampa, Florida 33612-9497, United States
  • Blood & Marrow Transplant Group of Georgia
    Atlanta, Georgia 30342, United States
  • University of Mississippi Medical Center, Div of Hematology
    Jackson, Mississippi 39216, United States
  • Kansas City Cancer Centers
    Kansas City, Missouri 64111, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Virginia Commonwealth University - Massey Cancer Center
    Richmond, Virginia 23298-0037, United States
  • University of Wisconsin, Blood and Bone Marrow Transplant
    Madison, Wisconsin 53792-5156, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2005, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2010, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2006
First posted
Nov 6, 2006
Start
Oct 2005
Primary completionActual
Dec 2009
CompletionActual
Dec 2009
Results first posted
Dec 2, 2010
Last update
Mar 13, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00396331
Responsible party
Sponsor
First posted
Nov 6, 2006
Start date
Oct 2005
Primary completion
Dec 2009
Completion
Dec 2009
Results posted
Dec 2, 2010
Last update
Mar 13, 2014

Study contacts

Medical Monitor
study director · Genzyme, a Sanofi Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Granulocyte Colony-Stimulating Factor · Plerixafor

Start the discussion